Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An announcement from Cabaletta Bio ( (CABA) ) is now available.
Cabaletta Bio has announced significant progress in its clinical development program for rese-cel, enrolling patients across multiple trials targeting diseases like pemphigus vulgaris, juvenile myositis, myasthenia gravis, and multiple sclerosis. The company aims to expand its clinical supply and manufacturing options with Lonza to support increased trial enrollment and prepare for potential registrational trials. Strategic priorities for 2025 include aligning with the FDA on trial designs, completing dosing in disease-specific cohorts, and presenting new data throughout the year to advance patient access and treatment experience.
More about Cabaletta Bio
Cabaletta Bio is a biotechnology company specializing in developing targeted cell therapies for autoimmune diseases. Their primary product, rese-cel, is a CD19-CAR T cell investigational therapy aimed at resetting the immune system to provide compelling clinical responses without ongoing therapy requirements. The company’s efforts are focused on a broad range of autoimmune diseases in therapeutic areas such as rheumatology, neurology, and dermatology.
YTD Price Performance: -10.94%
Average Trading Volume: 2,470,144
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $101.4M
Find detailed analytics on CABA stock on TipRanks’ Stock Analysis page.
